Pickwickian Syndrome (Obesity Hypoventilation Syndrome)

Origin of the Name

Definition

1. Obesity (BMI ≥ 30 kg/m²)
2. Chronic alveolar hypoventilation with daytime hypercapnia (awake PaCO₂ ≥ 45 mm Hg)
3. Sleep-related breathing disorder
4. Absence of other causes of hypoventilation (it is a diagnosis of exclusion)

Epidemiology

• Prevalence of 10-20% in obese OSA patients referred to sleep centers
• Nearly 50% in hospitalized patients with BMI ≥ 50 kg/m²
• Approximately 0.3% in the general U.S. adult population
• Prevalence is rising as super-obesity (BMI ≥ 50) increases

Pathophysiology

• Excess abdominal and perithoracic fat displaces the diaphragm rostrally, reducing its mechanical efficiency
• Reduced chest wall and respiratory system compliance
• Increased airway resistance and expiratory flow limitation
• Intrinsic PEEP, basilar atelectasis, and V/Q mismatch

• ~90% of OHS patients have co-existing OSA
• During obstructive events, CO₂ loads accumulate; compensatory hyperventilation between events becomes progressively inadequate over time
• During REM sleep, muscle atonia further worsens hypoventilation

• Blunted hypercapnic ventilatory response (HCVR)
• Blunted hypoxic ventilatory response
• Central hypothalamic "resistance" to leptin (leptin is an adipokine that normally stimulates ventilation; leptin resistance impairs this protective effect)
• Renal bicarbonate retention as metabolic compensation for chronic CO₂ retention further blunts the central drive to breathe

Clinical Presentation

• Excessive daytime sleepiness (hallmark) - even beyond what OSA alone explains
• Morning headaches (from nocturnal hypercapnia)
• Loud snoring, witnessed apneas
• Dyspnea on exertion (more prominent than in eucapnic OSA)

• Morbid obesity
• Facial plethora, injected sclerae
• Prominent pulmonic component of S2 (pulmonary hypertension)
• Lower extremity edema (right heart failure / cor pulmonale)
• Awake hypoxemia: PaO₂ typically < 70 mm Hg (uncommon in eucapnic OSA)

• Higher rates of systemic hypertension, angina, congestive heart failure
• Cor pulmonale and pulmonary hypertension
• Polycythemia (secondary erythrocytosis from chronic hypoxia)
• Increased ICU admissions; can present in acute-on-chronic hypercapnic respiratory failure

Diagnosis

Treatment

1. Positive Airway Pressure (PAP) - First-line

• Effective in 60-80% of OHS patients (particularly those with moderate-to-severe OSA phenotype / high AHI)
• Improves hypercapnia by unloading accumulated CO₂ from repetitive obstructive events
• Improves sleep quality, daytime sleepiness, and quality of life
• If hypercapnia persists after 2 months of adherent CPAP, transition to NIPPV

• Indicated for: low AHI phenotype, CPAP non-responders, acute decompensation
• Typical settings: EPAP 6-10 cm H₂O, IPAP 16-20 cm H₂O, pressure support difference ≥ 8-10 cm H₂O
• A backup respiratory rate (set ~2 breaths/min below waking RR) is recommended given ventilatory control abnormalities
• Prolonged inspiratory times are important to allow uniform tidal volume delivery and atelectasis recruitment

• Automatically adjusts pressure support to maintain a target tidal volume (e.g. when effort decreases in REM sleep)
• Useful for OHS but data comparing it to standard BiPAP are limited

2. Oxygen Supplementation

• Required in up to 50% of OHS patients in addition to PAP to maintain SpO₂ > 90%
• Oxygen alone is contraindicated - it can prolong apnea duration and worsen hypercapnia
• Oxygen must always be combined with NIPPV

3. Weight Loss

• Should be encouraged in all patients; even modest weight loss improves outcomes
• Often difficult to sustain with lifestyle measures alone
• Newer agents such as semaglutide (GLP-1 agonist) are showing promise
• Bariatric surgery can lead to significant improvement or resolution of OHS and should be considered in eligible patients

Key Distinguishing Points vs. OSA Alone

Prognosis

Alport Syndrome

Definition

• Progressive nephritis → end-stage kidney disease (ESKD)
• Sensorineural hearing loss
• Ocular abnormalities

Molecular Basis - Type IV Collagen

• The six COL4A genes are arranged in back-to-back pairs on three chromosomes:
  • COL4A1/COL4A2 → chromosome 13
  • COL4A3/COL4A4 → chromosome 2
  • COL4A5/COL4A6 → X chromosome (Xq22-24)

Genetics - Three Forms

• 50% by age 30
• 80% by age 40
• Nearly 100% by age 60

• Truncating variants (large deletions, nonsense mutations) → ESKD before age 30 in up to 90%
• Missense / splice variants → slower progression, ESKD often after age 30

Clinical Features

Kidney

• Persistent microscopic hematuria - the universal presenting feature (often from childhood)
• Episodic gross hematuria, often triggered by respiratory infections or exercise, with flank or abdominal pain
• Proteinuria - mild early, increases progressively; nephrotic syndrome can occur
• Hypertension - a late manifestation
• Progressive renal failure → ESKD, typically between ages 16-35 in X-linked males

Hearing

• High-frequency sensorineural deafness in 30-50% of patients
• The lesion is cochlear (shown by brainstem auditory-evoked responses)
• Hearing loss is always accompanied by renal involvement, but severity does not correlate with renal disease severity
• Some families have hereditary nephritis without deafness

Ocular (15-30%)

• Anterior lenticonus (protrusion of the central lens into the anterior capsule) - virtually pathognomonic of Alport syndrome
• "Dot and fleck" macular retinopathy
• Keratoconus, spherophakia, myopia, cataracts, retinitis pigmentosa

Other (rare)

• Aortic dissections, aneurysms, dilation, aortic insufficiency
• Diffuse esophageal/tracheobronchial leiomyomatosis (associated with large COL4A5-COL4A6 deletions)
• Epstein syndrome (megathrombocytopenia + nephritis)
• Fechtner syndrome (nephritis + macrothrombocytopenia + Döhle-like inclusions + deafness + cataract)

Pathology

Light Microscopy (non-specific)

• Early (<5 years): may be normal; occasional superficial fetal glomeruli or interstitial foam cells
• Later: mesangial proliferation, matrix increase, irregular GBM thickening and lamellation
• Advanced: focal segmental glomerulosclerosis (FSGS) pattern, tubular atrophy, interstitial fibrosis
• Note: a significant proportion of familial FSGS without apparent GBM lamellation may harbor COL4 mutations

Immunofluorescence (key diagnostic tool)

• Often negative (no immune complex deposits - helps exclude immune GN)
• Commercially available antisera to collagen IV α-chains show:
  • In X-linked males: absent α3, α4, α5 from GBM; absent α5 from Bowman's capsule, distal TBM, and skin
  • In XLAS females: segmental/mosaic loss of α5 in GBM and skin (due to X-inactivation)
  • In ARAS: absent α3, α4, α5 from GBM, but α5 retained in Bowman's capsule and skin (because α5 pairs with α6 there)

Electron Microscopy (definitive)

1. Early: GBM thinning (similar to thin basement membrane nephropathy)
2. Later: GBM thickening → irregular multilamellation of the lamina densa surrounding electron-lucent areas with electron-dense granules
3. Classic: "basket weave" or "split and splintered" appearance - pathognomonic

Diagnosis

• Persistent hematuria of unknown origin
• Proteinuria or kidney failure of unknown cause
• FSGS of unknown origin
• Family history of hereditary nephritis

Treatment

Renoprotective therapy (first-line, per 2024 guidelines)

• Significantly reduce proteinuria and delay progression to ESKD
• Early initiation provides the greatest benefit - recommended even in patients with microalbuminuria/hematuria alone in high-risk genotypes
• Benefit extends to heterozygous carriers with significant mutations

• The 2024 ERKNet/ERA/ESPN guideline recommends adding SGLT2i in adults with proteinuria and CKD
• Emerging evidence supports their nephroprotective role in AS

Emerging/investigational

• Anti-miR-21 (microRNA inhibitor) - clinical trials ongoing
• Bardoxolone methyl (Nrf2 activator)
• TGF-β inhibition, endothelin A antagonism (animal models)

Kidney transplantation

• Good long-term outcomes overall
• Risk: de novo anti-GBM nephritis in the allograft (because the donor kidney contains α3α4α5(IV) chains absent in the host → treated as foreign antigen)
• Anti-GBM antibodies detectable in a significant proportion but overt nephritis occurs in <3% of cases
• Important: relatives with heterozygous COL4A3/A4/A5 variants should be the last resort for living kidney donation (per 2024 guidelines), given their own risk of progression

Key Distinguishing Points

Robertsonian Translocation

Definition

• The total chromosome count drops from 46 to 45
• The karyotype is considered functionally balanced despite having only 45 chromosomes, because the lost short arms contain only ribosomal RNA genes (with hundreds of backup copies on the other acrocentric chromosomes) - their loss causes no clinical harm
• The resulting translocation chromosome is typically pseudodicentric (has two centromeric regions fused near each other)

Chromosomes Involved

Structure - What Happens

Carrier Phenotype

• Has 45 chromosomes (not 46)
• Is phenotypically normal - no clinical manifestations
• BUT carries significant risk of unbalanced offspring (see below)

Meiotic Segregation and Gamete Outcomes

Recurrence Risks

The 21q;21q Translocation - Special Case

• Every surviving pregnancy = Down syndrome (trisomy 21)
• Every non-surviving pregnancy = monosomy 21 (lethal)
• This is one of the very rare situations with >50% recurrence risk for abnormality

Clinical Significance

1. Translocation Down Syndrome

• Accounts for ~4% of all Down syndrome cases
• Patient has 46 chromosomes (not 47), but is trisomic for all genes on 21q
• Clinically identical to standard trisomy 21
• Key differences from standard trisomy 21:

• In ~2/3 of cases, the translocation is de novo in the child (low recurrence risk)
• In ~1/3 of cases, one parent is a balanced carrier (high recurrence risk) - this family requires "translocation tracing" to identify all at-risk relatives

2. Recurrent Pregnancy Loss (RPL)

• Balanced translocations are the most common chromosomal cause of RPL
• Found in 3-5% of couples with RPL vs. 0.2-0.7% in the general population
• Robertsonian translocations account for ~40% of these balanced translocations (reciprocal account for ~60%)
• Unbalanced gametes lead to trisomies or monosomies → miscarriage

3. Infertility

• Unbalanced segregation products predominantly result in miscarriage, reducing effective fertility

Karyotype Notation

• Balanced carrier (male): 45,XY,rob(14;21)(q10;q10)
• Down syndrome with translocation: 46,XY,rob(14;21)(q10;q10),+21
• rob(21;21) carrier: 45,XX,rob(21;21)(q10;q10)

Management / Genetic Counseling Points

1. Always karyotype a child with Down syndrome - not just to confirm diagnosis but to detect translocation vs. free trisomy
2. If translocation is found in the proband, karyotype both parents and then extend to relevant relatives ("translocation tracing / chasing")
3. Carriers should receive counseling about recurrence risk based on specific translocation and sex of carrier parent
4. Prenatal diagnosis (CVS or amniocentesis) is indicated in subsequent pregnancies of identified carriers
5. For rob(21;21) carriers - all pregnancies are at risk; preimplantation genetic testing (PGT) can be discussed as a route to unaffected offspring
6. Balanced carrier relatives with heterozygous Robertsonian translocations - consider implications for living kidney donation if co-existing renal conditions exist (per recent hereditary renal disease guidelines)

Turner Syndrome

Definition & Epidemiology

• Most common sex chromosome abnormality in females
• Incidence: approximately 1 in 2,000-3,000 live-born females
• Important: 45,X is the most common cytogenetic abnormality in spontaneously aborted fetuses - it accounts for ~18% of all chromosomally abnormal miscarriages. Only ~1% of monosomy X embryos survive to birth.

Karyotypes

1. Classic monosomy X (57%)

• 45,X - complete loss of one X chromosome
• Most severe phenotype

2. Structural abnormalities of the X chromosome (14%)

3. Mosaicism (29%)

• A 45,X cell line coexists with one or more other cell populations
• Common mosaic karyotypes:
  • 45,X / 46,XX (mildest - may have near-normal phenotype, primary amenorrhea only)
  • 45,X / 46,XY (mixed gonadal dysgenesis - risk of gonadoblastoma)
  • 45,X / 47,XXX
  • 45,X / 46,X,i(X)(q10)
• Note: With sensitive molecular techniques, mosaicism may be present in up to 75% of cases - conventional cytogenetics underestimates this

Origin of the Missing Chromosome

• In ~75-80% of cases, the retained X chromosome is maternal in origin
• This means the error is in paternal gametogenesis (the paternal sex chromosome, either X or Y, is lost)
• No maternal age effect (unlike autosomal trisomies)

Pathogenesis

Streak Ovaries - Key Mechanism

• Fetal ovaries develop normally during the first 18 weeks of gestation
• After week 18, absence of the second X leads to accelerated, irreversible oocyte loss, complete by age 2 years
• Result: ovaries become white fibrous streak gonads - devoid of ova and follicles
• Described memorably as: "menopause occurs before menarche"

SHOX Gene Haploinsufficiency

• SHOX haploinsufficiency → short stature (the primary molecular explanation for growth failure)
• SHOX is expressed in growth plates of long bones (radius, ulna, tibia, fibula)
• SHOX deletions also explain short stature in 2-5% of otherwise normal short children
• Conversely, excess SHOX copies in Klinefelter syndrome (47,XXY) → tall stature

Clinical Features

Neonatal / Infancy

• Peripheral lymphedema of the dorsum of hands and feet (lymph stasis) - a presenting sign
• Neck swelling due to dilated lymphatics → cystic hygroma → resolves leaving webbing
• Congenital heart disease detected early

Classic Features (Adolescents / Adults)

Diagnosis

Management (Multidisciplinary)

Growth - Recombinant Growth Hormone (rGH)

• Started early (before age 5-6 ideally) to maximize adult height gain
• Without treatment, final height rarely exceeds 150 cm
• Caveat: rGH worsens insulin resistance - monitor glucose

Hormone Replacement Therapy (HRT)

• Estrogen initiated at age-appropriate time (~11 years) to induce puberty:
  • Breast and uterine development
  • Supports linear growth
  • Maintains bone mineralization (prevents osteoporosis)
• Doses increased gradually over 2-4 years
• Progestins added later for withdrawal bleeds (endometrial protection)
• HRT maintained through normal menopausal age (~50 years)

Fertility

• Majority infertile; spontaneous pregnancy rare
• Successful pregnancy achieved via ovum donation + IVF in some women
• Risk: cardiac complications (aortic dissection risk is high during pregnancy) - requires expert counseling and careful cardiac monitoring

Cardiovascular Surveillance

• Regular cardiology follow-up throughout life
• Serial MRI of aortic root dimensions (preferred over echo for aorta)
• Antibiotic prophylaxis for dental/surgical procedures
• Aggressive blood pressure management
• Pregnancy contraindicated or very high-risk in those with aortic root dilation

Gonadoblastoma Risk (Y material)

• If Y chromosome sequences identified → gonadectomy traditionally recommended
• Modern approach: individualize decision weighing gonadal function potential and patient autonomy
• Intra-abdominal dysgenetic gonads carry up to 35% risk of germ cell cancer

Surveillance Schedule

Key Comparisons